Detail akcie Cerus Corp online

Business Summary: Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cerus Corp revenues decreased 1% to $186.8M. Net loss decreased 12% to $37.5M. Revenues reflect United States segment decrease of 3% to $123.7M, France segment decrease of 4% to $18.5M. Lower net loss reflects Stock-based Compensation in SGA decrease of 23% to $14.4M (expense), Other income, net increase from $1.7M (expense) to $1.8M (income).